Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century

Drugs

Volumn 76, Issue 7, 2016, Pages 741-757

  Rostoker, Guy ^a,d   Vaziri, Nosratola D ^b   Fishbane, Steven ^c  

^a Clinique de Parly 2   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d Service de Néphrologie et de Dialyse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23; HEPCIDIN; HEPCIDIN 25; IRON; UNCLASSIFIED DRUG;

ANEMIA; BLEEDING; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; FATALITY; GOLD STANDARD; HEMOCHROMATOSIS; HEMODIALYSIS PATIENT; HEMOSIDEROSIS; HUMAN; IATROGENIC DISEASE; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATIENT MONITORING; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; REVIEW; SUDDEN DEATH; ADVERSE EFFECTS; DIAGNOSTIC IMAGING; HEMODIALYSIS; LIVER; METABOLISM; PATHOPHYSIOLOGY;

HEMATINICS; HEPCIDINS; HUMANS; IATROGENIC DISEASE; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; RENAL DIALYSIS;

EID: 84964355087     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0569-0     Document Type: Review

References (113)

1. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007;18(2):382-93.
2. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-8.
3. Rostoker G, Griuncelli M, Loridon C, Cohen Y. Iatrogenic iron overload in dialysis patients. In: Suzuki H, editor. Updates in Hemodialysis. Rijeka: Intech; 2015. ISBN 978-953-51-2162-6.
4. KDOQI National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47 5 Suppl. 3:Sl6-85.
5. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006;1(Suppl 1):S9-18.
6. Ali M, Rigolosi R, Fayemi AO, et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet. 1982;1(8273):652-5.
7. Eschbach JW, Adamson JW. Iron overload in renal failure patients: change since the introduction of erythropoietin therapy. Kidney Int. 1999;55(Suppl 69):S35-43.
8. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125(10):991-9.
9. Vaziri ND. Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation. Am J Med. 2012;125(10):951-2.
10. Barton JC, Edwards CQ, Phatak PD, Britton RS, Bacon BR. Handbook of iron overload disorders. Cambridge: Cambridge University Press; 2010. ISBN-13: 9780521873437.
11. Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65(3):1091-8.
12. Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PloS One. 2012;7(12):e50295.
13. Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86(4):845-54.
14. Bailie GR, Larkina M, Goodkin DA, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87(1):162-8.
15. Gaweda AE, Ginzburg YZ, Chait Y, et al. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015;30(2):187-96.
16. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014;29(2):255-9.
17. Eknoyan G, Lameire N, Eckardt KU, et al. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279-335.
18. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R; On behalf of the ERA-EDTA ERBP advisory board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24(2):348-54.
19. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CP, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Glenn M. Chertow for conference participants. Iron management in chronic kidney disease: conclusions from a "kidney disease: improving global outcomes" (KDIGO) controversies conference. Kidney Int. 2016;89:28-39. doi: 10.1016/j.kint.2015.10.002.
20. Charytan DM, Pai AB, Chan CT, et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015;26(6):1238-47.
21. Yamamoto H, Tsubakihara Y. Limiting iron supplementation for anemia in dialysis patients: the basis for Japan's conservative guidelines. Semin Dial. 2011;24(3):269-71.
22. Himmelfarb J. Iron regulation. J Am Soc Nephrol. 2007;18(2):379-81.
23. Scientific advisory committee on nutrition. Iron and health. London: TSO; 2010.
24. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-84.
25. De Falco L, Sanchez M, Silvestri L, et al. Iron refractory iron deficiency anemia. Haematologica. 2013;98(6):845-53.
26. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004;22(1):112-23.
27. Otti T, Khajehdehi P, Fawzy A, et al. Comparison of blood loss with different high-flux and high-efficiency hemodialysis membranes. Am J Nephrol. 2001;21(1):16-9.
28. Kalocheretis P, Vlamis I, Belesi C, et al. Residual blood loss in single use dialyzers: effect of different membranes and flux. Int J Artif Organs. 2006;29(3):286-92.
29. Tsukamoto T, Yanagita M. Measurement of annual iron loss by blood sampling and residual blood after regular hemodialysis procedure in Japan. In: Annual Meeting of the American Society of Nephrology, Philadelphia (TH-PO858); 2014. https://www.asn-online.org/abstracts/.
30. Rottembourg J, Rostoker G. Use of intravenous iron supplementation in chronic kidney disease: interests, limits, and recommendations for a better practice. Neprol Therap. 2015. doi: 10.1016/jnephro.2015.04.009.
31. Rosenblatt SG, Drake S, Fadem S, et al. Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis. 1982;1(4):232-6.
32. Flint S, Taylor E, Beavis J, et al. Increased iron requirement in hemodialysis patients on antiplatelet agents or warfarin. Nephron Clin Pract. 2009;113(1):c38-45.
33. Goicoechea M, Caramelo C, Ochando A, et al. Antiplatelet therapy alters iron requirements in hemodialysis patients. Am J Kidney Dis. 2000;36(1):80-7.
34. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 2014;12(3):296-300.
35. Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Disease. 2013;7(1):9-22.
36. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(1):41-6.
37. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012;1:CD007857. doi: 10.1002/14651858.CD007857.pub2.
38. European Medicines Agency. Available from URL: http://www.emea.europa.eu. Accessed 26 Mar 2016.
39. Anastassiades EG, Howarth D, Howarth J, et al. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant. 1993;8(9):846-53.
40. Van Wyck DB. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin Nephrol. 1989;9(1 Suppl 2):21-4.
41. Mittman N. Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond. Am J Kidney Dis. 1999;34(1):173-5.
42. Freburger JK, Ng LJ, Bradbury BD, et al. Changing patterns of anemia management in US hemodialysis patients. Am J Med. 2012;125(9):906-14.
43. Pisoni RL, Fuller DS, Bieber BA, et al. The DOPPS practice monitor for US dialysis care: trends through August 2011. Am J Kidney Dis. 2012;60(1):160-5.
44. Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013;28(10):2570-9.
45. Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015;10(10):1814-21.
46. Ali M, Fayemi AO, Rigolosi R, et al. Hemosiderosis in hemodialysis patients: an autopsy study of 50 cases. JAMA. 1980;244(4):343-5.
47. Pitts TO, Barbour GL. Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron. 1978;22(4-6):316-21.
48. Gokal R, Millard PR, Weatherall DJ, et al. Iron metabolism in haemodialysis patients: aA study of the management of iron therapy and overload. Q J Med. 1979;48(191):369-91.
49. Simon P. Detoxification in hemosiderosis. Blood Purif. 1985;3(1-3):75-88.
50. Agroyannis B, Koutsicos D, Tzanatou-Exarchou H, et al. Combined recombinant human erythropoietin-blood letting strategy for treating anemia and iron overload in hemodialysis patients. Int J Artif Organs. 1991;14(7):403-6.
51. Cecchin E, De Marchi S, Querin F, et al. Efficacy of hepatic computed tomography to detect iron overload in chronic hemodialysis. Kidney Int. 1990;37(3):943-50.
52. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327-31.
53. Brissot P, Troadec MB, Bardou-Jacquet E, et al. Current approach to hemochromatosis. Blood Rev. 2008;22(4):195-210.
54. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program. 2009;2009:215-21. doi: 10.1182/asheducation-2009.1.215.
55. Alústiza JM, Castiella A, De Juan MD, et al. Iron overload in the liver: diagnostic and quantification. Eur J Radiol. 2007;61(3):499-506.
56. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93(5):741-52.
57. Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363(9406):357-62.
58. Rose C, Vandevenne P, Bourgeois E, et al. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol. 2006;77(2):145-9.
59. Olthof AW, Sijens PE, Kreeftenberg HG, et al. Non-invasive liver iron concentration measurement by MRI: comparison of two validated protocols. Eur J Radiol. 2009;71(1):116-21.
60. Castiella A, Alústiza JM, Emparanza JI, et al. Liver iron concentration quantification by MRI: are recommended protocols accurate enough for clinical practice? Eur J Radiol. 2011;21(1):137-41.
61. St Pierre TG, Clark PR, Chua-Anusom W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-61.
62. Carniero AA, Fernandes JP, De Araujo DB, et al. Liver iron concentration evaluated by two magnetic methods: magnetic resonance imaging and magnetic susceptometry. Magn Res Med. 2005;54(1):122-8.
63. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2∗mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-5.
64. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-9.
65. Hankins JS, McCarville MB, Loeffler RB, et al. R2∗magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20):4853-5.
66. Rostoker G, Cohen Y. Magnetic resonance imaging repercussions of intravenous iron products used for iron-deficiency anemia and dialysis-associated anemia. J Comput Assist Tomogr. 2014;38(6):843-4.
67. Rienso-European Medicines Agency. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002215/WC500129749.pdf. Accessed 18 Dec 2015.
68. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(1):77-83.
69. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87-93.
70. Fishbane S, Miyawaki N, Masani N. Hepatic iron in hemodialysis patients. Kidney Int. 2004;66(4):1714-5.
71. 52 Fe-labelled iron (III) hydroxide-sucrose complex following bolus administration using positron emission tomography. Br J Haematol. 1999;104(2):288-95.
72. Beshara S, Lundqvist H, Sundin J, et al. Pharmacokinetics and red cell utilization of iron (III) hydroxyde-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol. 1999;104(2):296-302.
73. 59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003;120(5):853-9.
74. Maker GL, Siva B, Batty KT, et al. Pharmacokinetics and safety of Deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton). 2013;18(3):188-93.
75. Alnahal AA, Tahan M, Fathy A, Fathy T. Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. Saudi J Kidney Dis Tranplant. 2014;25(4):808-13.
76. Agence Nationale de Sécurité du Médicament et des produits de Santé (ANSM). Traitement de l'anémie des hémodialysés par solutions de fer IV: l'ANSM rappelle la nécessité de respecter les schéma posologiques de l'AMM-Point d'information du 18/02/2013.ansm.sante.fr.
77. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15(6):1623-32.
78. Miskulin DC, Tangri N, Bandeen-Roche K, et al. Intravenous iron exposure and mortality in patients on hemodialysis. CJASN. 2014;9(11):1930-9.
79. Kshirsagar AV, Freburger JK, Ellis AR, Winkelmayer WC, Brookhart A. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. Plos One. 2013;8(11):e78930. doi: 10.1371/journal.pone.0078930 (eCollection 2013).
80. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. JASN. 2005;16(10):3070-80.
81. Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. JASN. 2013;24(7):1151-8.
82. Agarwal R, Kusek J, Pappas M. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015. doi: 10.1038/ki.2015.163.
83. Valenti L, Messa P, Pelusi S, et al. Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clin Chem Lab Med. 2014;52(5):613-9.
84. Van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013;28(12):3062-71.
85. Hyrszko T, Rydzewska-Rosolowska A, Brzosko S, et al. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial. 2012;16(2):146-51.
86. Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015. doi: 10.1016/j.cmet.2015.090.002
87. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RH. The elephant in uremia: oxidant stress as an unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-38.
88. Slotki I, Cabantchik ZI. The labile side of iron supplementation in CKD. J Am Soc Nephrol. 2015;26(11):2612-9.
89. Gaenzer H, Marschang P, Sturm W, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002;40(12):2189-94.
90. Drüeke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106(17):2212-7.
91. Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J. 2005;46(2):255-64.
92. Pahl MV, Vaziri ND. Immune function in chronic kidney disease. In: Kimmel P, Rosenberg M, editors. Chronic renal disease, chap 24. San Diego: Academic Press-Elsevier; 2015. p. 285-97. doi: 10.1016/B978-0-12-411602-3.00024-X.
93. Masuda Y, Ichii H, Vaziri ND. At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death. Am J Transl Res. 2013;6(1):64-70.
94. Fernández-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol. 2014;2(6):513-26.
95. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis. 2013;61(6):992-1000.
96. Ribeiro S, Belo L, Reis F, Santos-Silva A. Iron therapy in chronic kidney disease: recent changes, benefits and risks. Blood Rev. 2015. doi: 10.1016/j.blre.2015.07.006.
97. Drüeke TB, Massy ZA. Oral or intravenous iron for anemia correction in chronic kidney disease? Kidney Int. 2015;88(4):673-5. doi: 10.1038/ki.2015.189.
98. Tanaka S, Tanaka T. How to supplement iron in patients with renal anemia. Nephron Pract. 2015;131(2):138-44.
99. Polin V, Coriat R, Perkins G, et al. Iron deficiency: from diagnosis to treatment. Dig Liver Dis. 2013;45(10):803-9. doi: 10.1016/j.dld.2013.02.019 (Epub 2013 Apr 11).
100. Shibata M, Taniguchi S. Iron supplementation therapy in end-stage renal disease patients on maintenance hemodialysis. Cardiovasc Haematolog Disord Drug Targets. 2013;13:237-42.
101. Rostoker G, Griuncelli M, Loridon C, et al. Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis. Plos One. 2014;9(12):e115096. doi: 10.1371/journal.pone.0115096 (e Collection 2014).
102. Rostoker G, Griuncelli M, Loridon C, et al. Reassessment of iron biomarkers for prediction of dialysis iron overload: an MRI study. Plos One 2015;10(7):e0132006. doi: 10.1371/journal.pone.0132006 (eCollection 2015)
103. Ogawa C, Tsuchiya K, Kanda F, Maeda T. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients. Am J Nephrol. 2014;40(6):561-70.
104. Del Vecchio L, Locatelli F. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies. Expert Rev Hematol. 2014;7(4):495-506.
105. Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 2015. doi: 10.1038/ki.2015.203.
106. Umanath K, Jalal DI, Greco BA, for the Collaborative Study Group, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26(10):2578-87.
107. Qunibi WY. Is it too much of a good thing? A new era in phosphate binder therapy in ESRD. J Am Soc Nephrol. 2015;26(10):2311-3.
108. Nakanishi T, Hasuike Y, Nanami M, Yahiro M, Kuragano T. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited. Nephrol Dial Transplant. 2015. doi: 10.1093/ndt/gfv268.
109. ®: summary of the characteristics of the product. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205874s001lbl.pdf. Accessed 18 Dec 2015.
110. Vaziri ND, Zhao YY, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2015. doi: 10.1093/ndt/gfv095.
111. Vaziri ND, Yuan J, Rahimi A, et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant. 2012;27(7):2686-93.
112. Vaziri ND, Yuan J, Nazertehrani S, et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol. 2013;38(2):99-103.
113. EU Clinical Trials Register: Proactive IV Iron Therapy for Haemodialysis Patients (PIVOTAL), 2013. Available from URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB. Accessed 27 June 2014.